Enfermidades Infecciosas
Instituto de Biomedicina de Sevilla
Sevilla, EspañaPublications in collaboration with researchers from Instituto de Biomedicina de Sevilla (12)
2024
-
A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 79, Núm. 4, pp. 910-919
-
A comprehensive, predictive mortality score for patients with bloodstream infections (PROBAC): a prospective, multicentre cohort study
Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 8, pp. 1794-1800
-
Association of microbiological factors with mortality in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study
Clinical Microbiology and Infection, Vol. 30, Núm. 8, pp. 1035-1041
2023
2022
-
Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project
Microbiology spectrum, Vol. 10, Núm. 4, pp. e0005122
2021
-
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study
The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792
-
Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: Study protocol for the SAFO trial
BMJ Open, Vol. 11, Núm. 8
-
Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252
2020
-
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536
2018
-
Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort
Journal of Viral Hepatitis, Vol. 25, Núm. 6, pp. 699-706
2017
-
HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study
HIV Clinical Trials, Vol. 18, Núm. 3, pp. 126-134
-
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection
Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8